As of Oct 02
| +0.06 / +3.41%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 3.41, with a high estimate of 4.36 and a low estimate of 2.46. The median estimate represents a +87.39% increase from the last price of 1.82.
The current consensus among 2 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.